Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) announced that the company was in preliminary discussions with a number of potential strategic parties, "including with respect to a business combination that could provide the company with substantial capital." The company added: "However, the consummation of any such transaction would be subject to the negotiation and execution of definitive agreements containing customary conditions to closing. In addition, proceeding with the potential business combination would require that certain security instruments of the company be amended to eliminate the company's obligation to make a cash payment to the holders of such securities upon the consummation of a change in control transaction. There can be no assurance that any such transaction will be consummated".